Zuo P, Ogita K, Suzuki T, Han D, Yoneda Y
Department of Pharmacology, Setsunan University, Osaka, Japan.
J Neurochem. 1993 Nov;61(5):1865-73. doi: 10.1111/j.1471-4159.1993.tb09828.x.
Pretreatment with sulfhydryl-reactive agents, such as N-ethylmaleimide and p-chloromercuriphenylsulfonic acid, invariably resulted in marked inhibition of the binding of DL-(E)-2-amino-4-[3H]propyl-5-phosphono-3-pentenoic acid ([3H]CGP 39653), a competitive antagonist at an N-methyl-D-aspartate (NMDA)-sensitive subclass of central excitatory amino acid receptors, in brain synaptic membranes extensively washed and treated with Triton X-100, but did not significantly affect the binding of L-[3H]-glutamic acid ([3H]Glu), an endogenous agonist. The pretreatment was effective in reducing the binding of [3H]-CGP 39653 at equilibrium, without altering the initial association rate, and decreased the affinity for the ligand. Pretreatment with sulfhydryl-reactive agents also enhanced the potencies of NMDA agonists to displace [3H]-CGP 39653 binding and attenuated those of NMDA antagonists, but had little effect on the potencies of the agonists and antagonists to displace [3H]Glu binding. The binding of both [3H]CGP 39653 and [3H]Glu was similarly sensitive to pretreatment with four different proteases in Triton-treated membranes, whereas pretreatment with phospholipase A2 or C markedly inhibited [3H]CGP 39653 binding without altering [3H]Glu binding. Moreover, both phospholipases not only induced enhancement of the abilities of NMDA agonists to displace the binding of [3H]CGP 39653 and [3H]Glu, but also caused diminution of those of NMDA antagonists. These results suggest that both sulfhydryl-reactive agents and phospholipases may predominantly interfere with radiolabeling of the NMDA recognition domain in a state favorable to an antagonist by [3H]CGP 39653, with concomitant facilitation of that in an antagonist-preferring form by [3H]Glu. The possible presence of multiple forms of the NMDA recognition domain is further supported by these data.
用巯基反应剂(如N-乙基马来酰亚胺和对氯汞苯磺酸)进行预处理,总是会导致DL-(E)-2-氨基-4-[³H]丙基-5-膦酰基-3-戊烯酸([³H]CGP 39653)的结合受到显著抑制。[³H]CGP 39653是中枢兴奋性氨基酸受体中对N-甲基-D-天冬氨酸(NMDA)敏感亚类的竞争性拮抗剂,在经过广泛洗涤并用 Triton X-100处理的脑突触膜中,其结合受到抑制,但对内源性激动剂L-[³H]-谷氨酸([³H]Glu)的结合没有显著影响。预处理有效地降低了平衡时[³H]-CGP 39653的结合,而不改变初始结合速率,并降低了对配体的亲和力。用巯基反应剂进行预处理还增强了NMDA激动剂取代[³H]-CGP 39653结合的效力,并减弱了NMDA拮抗剂的效力,但对激动剂和拮抗剂取代[³H]Glu结合的效力影响很小。在Triton处理的膜中,[³H]CGP 39653和[³H]Glu的结合对用四种不同蛋白酶进行的预处理同样敏感,而用磷脂酶A2或C进行预处理则显著抑制[³H]CGP 39653的结合,而不改变[³H]Glu的结合。此外,两种磷脂酶不仅诱导NMDA激动剂取代[³H]CGP 39653和[³H]Glu结合的能力增强,而且还导致NMDA拮抗剂的能力减弱。这些结果表明,巯基反应剂和磷脂酶可能主要通过[³H]CGP 39653干扰处于有利于拮抗剂状态的NMDA识别域的放射性标记,同时促进[³H]Glu以偏好拮抗剂的形式进行标记。这些数据进一步支持了NMDA识别域可能存在多种形式的观点。